Which structural domain of an immunoglobulin molecule is responsible for binding to Fc receptors on immune cells?

Explanation

## Immunoglobulin Structure — Fc Region and Receptor Binding ### Antibody Architecture Overview ```mermaid flowchart TD A[Immunoglobulin Molecule]:::outcome --> B[Heavy Chain]:::outcome A --> C[Light Chain]:::outcome B --> D[Variable Domain VH]:::outcome B --> E[Constant Domains CH1, CH2, CH3]:::outcome C --> F[Variable Domain VL]:::outcome C --> G[Constant Domain CL]:::outcome D --> H[Antigen Binding Site]:::action F --> H E --> I[Fc Region - Receptor Binding]:::action G --> I ``` **Key Point:** The **Fc region** (Fragment crystallizable) consists of the constant domains of the heavy chain (CH2 and CH3) and the constant domain of the light chain (CL). This region is responsible for all effector functions, including Fc receptor binding. ### Fc Region Functions | Function | Mechanism | Fc Receptor Involved | |----------|-----------|----------------------| | **Opsonization** | Binding to FcγR on macrophages/neutrophils | FcγRI, FcγRII, FcγRIII | | **Complement activation** | Binding of C1q to CH2 domain | Classical pathway | | **ADCC** | NK cell engagement via FcγRIII | FcγRIII | | **Mast cell degranulation** | Binding to FcεR on mast cells (IgE) | FcεRI | | **Placental transfer** | Binding to FcRn in placental endothelium (IgG) | FcRn | **High-Yield:** The **CH2 domain** is the primary site of Fc receptor binding and contains N-linked glycosylation critical for receptor recognition. **Mnemonic:** **"Fab = Antigen binding, Fc = Effector function"** — The variable regions (Fab) bind antigen; the constant regions (Fc) mediate immune cell engagement. ### Why Other Domains Do NOT Bind Fc Receptors - **Variable domains (VH, VL):** Bind antigen, not Fc receptors - **Hinge region:** Provides flexibility between Fab and Fc arms; does not bind receptors - **J chain:** Connects IgM pentamers and IgA dimers; not involved in Fc receptor binding **Clinical Pearl:** Mutations or glycosylation defects in the Fc region impair immune cell activation, reducing opsonization and complement activation — a mechanism exploited in some therapeutic antibodies (e.g., afucosylated anti-CD20 for enhanced ADCC). [cite:Harrison 21e Ch 372]